The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.

MSD also said it would pause Gardasil sales in China until at least mid-2025. Another reason that was mentioned was weak discretionary spending. Because Gardasil is not part of China’s national ...

United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese ...

In vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 — fell 18% to $1.55 billion due to lower demand in China, partially offset by higher sales in most international markets ...